TABLE 2.
Clinical correlation of fluconazole MICs determined by two different methods for testing C. neoformans isolates from 35 Ugandan AIDS patients with meningitisa
| Fluconazole MIC (μg/ml) | No. of patients with the indicated clinical outcome by test method
|
|||||||
|---|---|---|---|---|---|---|---|---|
| YNBb
|
NCCLS M27-Ac
|
|||||||
| Tested | Cured | Failed | Diedd | Tested | Cured | Failed | Died | |
| 0.5 | 2 | 2 | ||||||
| 1.0 | 5 | 3 | 1 | 1 | ||||
| 2.0 | 9 | 6 | 2 | 1 | 1 | 1 | ||
| 4.0 | 11 | 3 | 4 | 4 | 15 | 7 | 5 | 3 |
| 8.0 | 8 | 4 | 1 | 3 | 18 | 8 | 3 | 7 |
| 16 | 1 | 1 | ||||||
All patients were treated with fluconazole at doses of 400 to 1,200 mg/day.
YNB, microdilution method using yeast nitrogen base medium and spectrophotometric reading at 48 h.
NCCLS M27-A, reference microdilution method read visually after 48 h of incubation.
Patients who died within the first 10 weeks of therapy (five with positive CSF cultures).